Global Liquid Biopsy Market to 2024 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad Labs, Biocept, Biocartis, Myriad Genetics, Genomic Health, NeoGenomics Laboratories, & Qiagen

DUBLIN, Feb. 20, 2019 /PRNewswire/ --

The "Liquid Biopsy Market, Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies" report has been added to's offering.

Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.

Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient's tumor and provide clues about the treatment that a patient's needs.

Scope of the Report

By Cancer - Lung Cancer Controls the Liquid Biopsy Market

The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market.

By Product - Majority of Liquid Biopsy Market held by Kits & Consumables

The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments.

By Circulating Biomarkers

The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share

By Sample - Plasma/Serum accounts for the maximum market

In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

By Clinical Application - Screening Purpose leads the Liquid Biopsy Market

The report studies the market of the following clinical application segments: Monitoring, Prognosis, Theranostics & Screening.

By Region - North America and Europe will drive the Liquid Biopsy Market

North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market.

Companies Analysis

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report.

Key Topics Covered:

1. Executive Summary

2. Global - Liquid Biopsy Market

3. Market Share - Global Liquid Biopsy
3.1 By Region
3.2 By Cancer
3.3 By Product
3.4 By Circulating Biomarkers

4. Region - Liquid Biopsy Market
4.1 North America
4.2 Europe
4.3 Asia - Pacific
4.4 Latin America
4.5 Middle East & Africa

5. Cancer - Liquid Biopsy Market
5.1 Lung Cancer
5.2 Breast Cancer
5.3 Colorectal Cancer
5.4 Prostate Cancer
5.5 Others

6. By Product - Liquid Biopsy Market
6.1 Kits & Consumables
6.2 Instruments
6.3 Services

7. Circulating Biomarkers - Liquid Biopsy Market
7.1 Circulating Tumor Cells (CTCs)
7.2 Circulating Tumor DNA (ctDNA)
7.3 Exosomes

8. By Clinical Application - Liquid Biopsy Market
8.1 Monitoring
8.2 Prognosis
8.3 Theranostics
8.4 Screening

9. By Sample - Liquid Biopsy Market
9.1 Plasma / Serum
9.2 Urine
9.3 Others

10. Thermo Fisher Scientific Inc - Company Analysis

11. Roche Diagnostics - Company Analysis

12. Bio - Rad Laboratories Inc - Company Analysis

13. Biocept, Inc. - Company Analysis

14. Biocartis - Company Analysis

15. Myriad Genetics, Inc - Company Analysis

16. Genomic Health - Company Analysis

17. NeoGenomics Laboratories - Company Analysis

18. Qiagen - Company Analysis

19. Growth Drivers
19.1 Real - Time Evaluation, Convenient and Accuracy
19.2 Increasing Demand for Minimally - Invasive Biopsy Techniques
19.3 Technical Advancement & Personalized Therapies

20. Challenges
20.1 Barriers for Liquid Biopsies
20.2 High Cost with Uncertain or Limited Reimbursement for Liquid Biopsy

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets